Long-Term Efficacy Outcomes of Natalizumab vs. Fingolimod in Patients With Highly Active Relapsing-Remitting Multiple Sclerosis: Real-World Data From a Multiple Sclerosis Reference Center.

Front Neurol · 2021 · PMC8419322 · PMID 34497577

Europe PMC DOI

hedged sentence

0.0940

closest p · 1.9× alpha

0.0940

boldest claim

The sentences

did not reach statistical significancep = 0.094so close (0.05 < p ≤ 0.1)

Overall, treatment discontinuation occurred earlier on average for 29 FTY-treated patients compared to 70 patients under NTZ, however, the difference in the mean treatment duration did not reach statistical significance (treatment duration in months: 38.17 ± 4.38 vs. 49.8 ± 3.75, p = 0.094).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.